Jasmine M. Manouchehri
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
26
Citations
228
Est. group size
~9
Recurring co-author estimate
Active years
10
Publishing since 2016
Jasmine M. Manouchehri's research focuses on breast cancer biology, particularly how to make resistant tumor cells more responsive to chemotherapy and other treatments. Her work examines cell signaling pathways involving estrogen receptors, extracellular ATP (a cellular signaling molecule tied to immune responses and cell death), and heparan sulfate (a sugar-based molecule on cell surfaces), especially in triple-negative and endocrine-resistant breast cancers. Much of this work combines lab experiments with animal models (xenografts) to test potential therapeutic strategies.
Publication output has been steady over the past decade, with a small dip in 2019 followed by consistent activity of roughly 2-4 papers per year through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells
Frontiers in Oncology · 2025
- Abstract 6800: Extracellular ATPase inhibitor-chemotherapy treatment of macrophages increases danger signal extracellular ATP to induce inflammatory pyroptotic cell death
Cancer Research · 2025
- Potent Estrogen Receptor β Agonists with Inhibitory Activity <i>In Vitro</i> , Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abstract 3276: The effects of extracellular ATP signaling on the anticancer activities of macrophages
Cancer Research · 2024
- Abstract 398: The inhibition of sulfation of heparan sulfate augments the chemotherapeutic response in triple-negative breast cancer
Cancer Research · 2023
- Abstract 397: The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer
Cancer Research · 2023
- The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Sulfatase 2 Inhibition Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy Through Augmentation of Extracellular ATP
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
Frontiers in Oncology · 2022
- Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Abstract PS18-39: Estrogen receptor beta agonists for triple negative breast cancer
Cancer Research · 2021
- Abstract PD15-08: The role of purinergic signaling in the chemotherapy response of triple negative breast cancer
Cancer Research · 2021
- Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
Frontiers in Oncology · 2020
- Abstract 5158: Estrogen receptor β agonists: A novel therapeutic strategy for breast cancer
Cancer Research · 2020
- TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment
Breast Cancer Basic and Clinical Research · 2018
- Cancer Research×10
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Frontiers in Oncology×4
- Anticancer Research×2
- Breast Cancer Basic and Clinical Research×1
- Yan Yang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Santosh Philips
Biochemistry, Genetics and Molecular Biology · Indiana University
- Heather L. Walker
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Christopher C. Coss
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Hanieh Taheri
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile